CHINA & GERMANY
Research driven pharmaceutical company Boehringer Ingelheim, in partnership with Taizhou China Medical City in Jiangsu Province, China, held a ground-breaking ceremony for a veterinary vaccine manufacturing plant at the China Medical City (Taizhou China Medicine High-Tech Development Zone) last week (Friday, 16 August).
US - Controlling swine diseases such as Porcine Reproductive and Respiratory Syndrome (PRRS), Porcine Circovirus Associated Disease (PCV2) and Mycoplasma pneumonia (M. hyo) is one of the the key challenges for producers and veterinarians. During the 2012 World Pork Expo, swine experts discussed the impacts of these diseases, the latest research and effective ways to manage respiratory diseases on modern production farms.
US - The research driven pharmaceutical company Boehringer Ingelheim will expand its global animal health vaccines business. With the completion of a series of major investments at the US site in St. Joseph, Missouri, the company will further enhance its position in the development and supply of vaccines against the most important diseases of pigs.
Boehringer Ingelheim yesterday announced the expansion of its Animal Health business in China. One of the major moves is the opening of the Asian Veterinary Research & Development (R&D) Center in Zhangjiang, Shanghai.
Progesterone in the uterus blocks milk production. Only when the birth process is complete and the after-births have been delivered does this blocker stop.
Prolactin is important, especially in the last third of gestation, for proper udder-development. Furthermore prolactin is the main milk-promoting hormone during lactation.
Be aware of endotoxins and inflammations in the sow! Endotoxins i.e E.coli endotoxins and inflammatory processes inhibit these milk-hormones.
BARCELONA, SPAIN - An important anniversary in the history of porcine circovirus type 2 (PCV2) has been marked at a special international pig veterinary satellite symposium held in Barcelona, Spain in June 2011 as part of the 6th International Symposium on Emerging and Re-emerging Pig Diseases.
Boehringer Ingelheim Animal Health has decided to remain focused on freshly mixed Porcine Circovirus type 2 (PCV2)/ Mycoplasma hyopneumoniae (M.hyo) vaccines and not follow the development of a PCV2/M.hyo ready-to-use (RTU) vaccine combination. As a consequence of this decision, the company has discontinued its PCV2/M.hyo RTU research program.
Get the latest news on Swine Health Subscribe to our newsletter